



This is an open access article distributed in accordance with the Creative Commons Attribution (CC BY 4.0) license: <https://creativecommons.org/licenses/by/4.0/> which permits any use, Share — copy and redistribute the material in any medium or format, Adapt — remix, transform, and build upon the material for any purpose, as long as the authors and the original source are properly cited. © The Author(s) 2025

Frequency of neoplastic and non-neoplastic lesions of the thyroid gland in tertiary care Hospitals of Lahore

Raja Yasser Shahbaz¹, Natalia Malik^{2*}, Amna Sohail², Mustafa Qadeer³, Faiqua Yasser⁴, Hina Zafar Raja⁵

ABSTRACT

Background and Objective: Thyroid lesions stand as the predominant endocrine disorders witnessing a substantial global surge in the incidence over recent decades. This study was designed to assess the frequency of neoplastic and non-neoplastic thyroid lesions, focusing on variations across age groups and genders within two tertiary care hospitals in Lahore, Pakistan.

Methods: This retrospective cross-sectional study was conducted at the Pathology Departments of Combined Military Hospital Lahore and Sheikh Zayed Hospital Lahore from the year 2017 to 2021. Histopathological data of 1,217 patients was assessed, with 333 patients having thyroid lesions. The lesions were classified into neoplastic and non-neoplastic. Statistical analysis was performed using the Chi-square test.

Results: Among the 1,217 patients, 333 (27.3%) were diagnosed with thyroid-related lesions, of which 303 (90.9%) were neoplastic and 30 (9.0%) were non-neoplastic. Neoplastic lesions included multinodular goiter (41.4%), adenomatous colloid goiter (32.7%), papillary carcinoma (10.2%), and follicular adenoma (6.6%). Non-neoplastic lesions comprised Hashimoto's thyroiditis (8.1%) and thyroglossal cysts (0.9%). The frequency of thyroid lesions was significantly higher in males (56.6%) ($p = 0.001$). There was a statistically significant variation in the distribution of lesion types across different age groups ($p < 0.001$).

Conclusion: Papillary carcinoma emerged as the sole malignant thyroid lesion identified, highlighting its prominence within the study population. These findings underscore the necessity for region-specific epidemiological research to better understand thyroid pathology and inform targeted screening and management strategies.

Keywords: Thyroid, histopathology, lesions, neoplastic, non-neoplastic.

Received: 20 June 2024

Revised date: 03 August 2024

Accepted: 15 September 2024

Correspondence to: Dr. Natalia Malik

*Resident Prosthodontic Department, Institute of Dentistry, CMH Lahore Medical College, Lahore, Pakistan.

Email: nat190219021902@gmail.com

Full list of author information is available at the end of the article.

Introduction

Thyroid lesions encompass a wide spectrum of pathologies including neoplastic and non-neoplastic lesions. Neoplastic lesions include both benign entities such as follicular adenoma, adenomatous colloid goiter, and multinodular goiter, as well as malignant tumors like papillary carcinoma, follicular carcinoma, medullary carcinoma, and anaplastic carcinoma.¹ Non-neoplastic lesions primarily involve inflammatory conditions, with Hashimoto's thyroiditis being the most prevalent, alongside congenital anomalies like thyroglossal duct cysts.²

Among endocrine malignancies, thyroid cancer (TC) is the most common, with a global incidence that has been steadily increasing over recent decades. This rise is attributed to several factors including enhanced diagnostic techniques,

increased exposure to environmental carcinogens, and potential genetic predispositions.³ The incidence of cold nodules reaches a notable increase from 4% to 15.6% in different studies.^{4,5} In studies reported from Pakistan, Saudi Arabia, and the United Arab Emirates, more frequency of thyroid nodules has been seen in females.⁶⁻⁸ Multinodular goiter and papillary carcinoma are the leading benign and malignant lesions, respectively, in the local population.⁹

In Pakistan, studies have indicated an upward trend in TC incidence, particularly in urban centers such as Karachi and Quetta. In Karachi, papillary carcinoma was reportedly the most frequent malignancy, predominantly in females with most patients in their fourth decade of life.¹⁰ In Quetta, Balochistan, TC was more common in females than males, with

57 papillary carcinoma being the most common malignancy.¹¹
58 In Hyderabad, Pakistan, 7.6% of the multinodular goiter had
59 malignancy with papillary carcinoma.¹² Determining the
60 incidence of thyroid carcinoma in Pakistan is challenging due
61 to the lack of comprehensive population-based data.¹⁰

62 The study aimed to determine the frequency of both
63 neoplastic and non-neoplastic thyroid lesions presenting
64 in leading tertiary care hospitals of Lahore, Pakistan, while
65 analyzing and comparing their distribution across various age
66 groups and genders.

67 **Methods**

68 This research was conducted as a cross-sectional study
69 where retrieval and analysis of existing histopathological
70 data collected over the past 4 years, i.e., 2017–2021 was
71 done from the Pathology Departments of Combined
72 Military Hospital (CMH) Lahore and Sheikh Zayed Hospital,
73 Lahore, after the approval of the Ethical Committee of CMH
74 Lahore Medical College, Lahore, Pakistan. Histopathological
75 departments at these institutes maintain an up-to-date
76 record including clinical history and pathology reports. From
77 this dataset, lesions associated with the thyroid gland were
78 identified and categorized into neoplastic and non-neoplastic
79 types. Key demographic and clinical details, including age,
80 sex, and the histopathological classification of each lesion,
81 were meticulously documented alongside the corresponding
82 biopsy diagnosis. The inclusion criteria comprised patients of
83 any age presenting with a solitary lesion (benign, malignant,
84 or inflammatory) located in the thyroid region exclusively. In
85 contrast, the exclusion criteria were lesions exhibiting normal
86 histology, as well as lesions lacking definitive pathology or
87 having insufficient data.

88 The study population was divided into having neoplastic
89 and non-neoplastic lesions of the thyroid according to the
90 World Health Organization Classification of Tumors of the
91 Thyroid Gland, 2022 Edition.¹³

92 Neoplastic lesions included: Benign: Follicular Adenoma,
93 Adenomatous Colloid Goiter, Multinodular Goiter, and
94 Malignant: Papillary carcinoma. Non-neoplastic lesions
95 included Thyroiditis: Hashimoto's Thyroiditis, Cysts such as
96 thyroglossal cyst etc.

97 The study categorized the patient ages into five distinct
98 groups to better analyze the distribution of thyroid lesions by
99 sex and age. These groups were: Group 1, encompassing ages
100 1-18 years; Group 2, including individuals aged 19-35 years;
101 Group 3, for ages 36-50 years; Group 4, comprising ages
102 51-70 years; and Group 5, for those aged 70 years and above.
103 This classification allowed for a detailed examination of how
104 the frequency of thyroid lesions varied across different age
105 ranges and between genders.

Statistical analysis

106 Data analysis was conducted utilizing the Statistical Package for
107 Social Sciences software, version 17.0, designed for Windows.
108 The relative frequencies of different histological types of
109 thyroid lesions were calculated and tabulated. The chi-square
110 test was employed to assess variations in histological types
111 across gender and age groups. Statistical significance was
112 established at p values less than or equal to 0.05.
113

Results

114 A total of 1,217 patients who presented with lesions in the
115 neck region in the Department of Pathology, Sheikh Zayed
116 Hospital, and CMH, Lahore, 333 patients were diagnosed with
117 thyroid-related abnormalities. The neoplastic lesions consisted
118 of multinodular goiter, adenomatous colloid goiter, follicular
119 adenoma, and papillary carcinoma. The non-neoplastic lesions
120 consisted of the thyroglossal cyst and Hashimoto's thyroiditis.
121

122 The frequency of different types of thyroid lesions is
123 tabulated in Table 1. Among the 333 evaluated thyroid lesions,
124 the findings revealed 138 (41.4%) cases of Multinodular
125 Goitre and 109 (32.7%) cases of Adenomatous Colloid Goitre.

126 The gender-wise distribution of thyroid lesions is shown
127 in Tables 2 and 3. There was a significant difference in the
128 scores for males (4.96 ± 1.94) and females (4.53 ± 2.33); (χ^2
129 = 3.46, $p = 0.001$). The most common abnormality in males
130 was adenomatous colloid goiter ($n = 77$, 40.9%), whereas
131 multinodular goiter was most frequent in females ($n = 75$,
132 51.7%) (Tables 2 and 3).

133 The age-wise distribution of neoplastic and non-neoplastic
134 thyroid lesions is shown in Table 4. The study revealed a
135 statistically significant difference between age groups and the
136 distribution of various thyroid lesions ($\chi^2 = 65.687$, $p < 0.001$)
137 (Table 5). This table shows that the highest frequency of the
138 lesions (42%) was seen in the age group of 19-35 years ($p < 0.01$).

Discussion

139 In this study, a total of 27.3% patients were diagnosed with
140 thyroid-related abnormalities, and of these, the majority
141 (91%) were neoplastic. This high frequency of neoplastic
142 lesions aligns with the global trends.^{14,15} Moreover, previous
143 studies conducted in other regions of Pakistan such as
144 Karachi, Balochistan, and Peshawar reported a higher
145 incidence of neoplastic lesions and most of them were
146 benign compared to malignant ones.^{11,16,17} The predominance
147 highlights the significant burden of benign thyroid disorders,
148 which, while not malignant, require clinical attention to
149 prevent complications such as compressive symptoms and
150 potential malignant transformation.^{15,17} The high proportion
151 of neoplastic lesions emphasizes the necessity for targeted
152 diagnostic and therapeutic strategies to manage these
153 conditions effectively.^{3,14}
154

155

Table 1. Frequency of different types of thyroid lesions during the study period.

Lesions		n	%
Neoplastic	Multinodular goiter	138	41.4
	Follicular adenoma	22	6.6
	Papillary carcinoma	34	10.3
	Adenomatous colloid goiter	109	32.7
Non- neoplastic	Hashimoto's thyroiditis	27	8.1
	Thyroglossal cyst	3	0.9

Table 2. Gender-wise distribution of thyroid lesions.

Gender	Neoplastic				Non- neoplastic		Total
	Multinodular goiter	Follicular adenoma	Papillary carcinoma	Adenomatous colloid goiter	Hashimoto's thyroiditis	Thyroglossal cyst	
Male	63 (33.5)	14 (7.4)	16 (8.6)	77 (40.9)	17 (9.1)	1 (0.5)	188 (56.5)
Female	75 (51.7)	8 (5.6)	18 (12.4)	32 (22.1)	10 (6.9)	2 (1.3)	145 (43.5)
Total	138 (41.4)	22 (6.7)	34 (10.2)	109 (32.7)	27 (8.1)	3 (0.9)	333 (100)

157

Table 3. Gender-wise comparison of thyroid lesions.

Gender	n (%)	Mean±SD	χ^2	p-value*
Male	188 (56.5)	4.96 ± 1.943	3.463	0.001
Female	145 (43.5)	4.53 ± 2.334		

158

*Chi-square test

Table 4. Age-wise distribution of thyroid lesions.

Age (Years)	Thyroid						Total
	Neoplastic				Non-neoplastic		
	Multinodular goiter	Follicular adenoma	Papillary carcinoma	Adenomatous colloid goiter	Hashimoto's Thyroiditis	Thyroglossal cyst	
1-18	6 (1.8)	2 (0.6)	2 (0.6)	1 (0.3)	1 (0.3)	0 (0)	12 (3.6)
19-35	64 (19.2)	5 (1.5)	16 (4.8)	42 (12.6)	11 (3.3)	2 (0.6)	140 (42.0)
36-50	52 (15.6)	11 (3.3)	11 (3.3)	28 (8.4)	12 (3.6)	0 (0)	114 (34.2)
51-70	16 (4.8)	3 (0.9)	4 (1.2)	32 (9.6)	3 (0.9)	1 (0.3)	59 (17.7)
70+	0 (0)	1 (0.3)	1 (0.3)	6 (1.8)	0 (0)	0 (0)	8 (2.4)
Total	138 (41.5)	22 (6.6)	34 (10.2)	109 (32.7)	27 (8.1)	3 (0.9)	333 (100)

160 In the current study, among the neoplastic thyroid lesions,
 161 multinodular goiter was the most prevalent, accounting for
 162 41.4% of cases, followed by adenomatous colloid goiter at
 163 32.7%, papillary carcinoma at 10.2%, and follicular adenoma at
 164 6.6%. This distribution is consistent with international findings,
 165 where multinodular goiter is recognized as the most common
 166 benign thyroid disorder.^{14,18,19} Similar studies in other parts
 167 of Pakistan have reported multinodular goiter as the leading
 168 thyroid neoplasm, reinforcing the consistency of this trend.^{10,11,20}

169 The current study reports a higher frequency of thyroid
 170 lesions in males compared to females, with adenomatous
 171 colloid goiter being the most common lesion occurring in males

172 and multinodular goiter being more frequent in females. This
 173 male predominance contrasts with global epidemiological
 174 patterns, especially in countries such as Saudi Arabia and the
 175 United States where thyroid disorders, including cancers, are
 176 generally more prevalent in females.^{4,7,9,21,22} This discrepancy
 177 may be influenced by regional factors such as occupational
 178 exposures, lifestyle differences, or genetic, hormonal, and
 179 autoimmune predispositions.^{20,21} Further investigation
 180 into these gender-specific etiological factors is essential to
 181 understand the underlying causes.

182 The age-wise distribution of thyroid lesions in our study
 183 demonstrates a significant variation with multinodular

184 **Table 5.** Age-wise comparison of thyroid lesions.

Age (Years)	n (%)	χ^2	p-value*
1-18	12 (3.6)	24.36	<0.001*
19-35	140 (42.0)		
36-50	114 (34.2)		
51-70	59 (17.7)		
70+	8 (2.4)		
Total	333 (100)		

185 *Chi-square test

186 goiter, papillary carcinoma, adenomatous colloid goiter,
 187 and thyroglossal cysts most frequently occurring in the
 188 19-35 years age group, while Hashimoto's thyroiditis was
 189 more commonly diagnosed in individuals aged 36-50 years.
 190 This younger demographic trend is not consistent with the
 191 global data, which typically shows a higher incidence in
 192 middle-aged populations.^{23,24} The younger age distribution
 193 may reflect regional differences in genetic factors,
 194 environmental exposures, or healthcare access. In addition,
 195 the significant prevalence of Hashimoto's thyroiditis in the
 196 36-50 years age group aligns with global observations linking
 197 autoimmune thyroiditis with middle-aged populations,
 198 reflecting the chronic nature of autoimmune disorders and
 199 their progression over time.^{5,16,25} The significant variation in
 200 lesion prevalence across different age groups underscores
 201 the dynamic nature of thyroid pathology and its association
 202 with age-related physiological changes²⁶.

203 The predominance of papillary carcinoma as the sole
 204 malignant thyroid lesion in the current study emphasizes the
 205 need for targeted screening and early diagnostic strategies.
 206 Given its high prevalence prognosis, early detection can
 207 significantly improve patient outcomes and reduce mortality.^{3,4}

208 Limitations of the Study

209 This study is limited by its retrospective design and reliance
 210 on data from only two tertiary care hospitals, which may
 211 not represent the broader population and may affect the
 212 generalizability of the findings. In addition, the absence of
 213 detailed information on potential confounding factors such
 214 as family history, environmental exposures, and lifestyle
 215 factors limits the ability to draw definitive conclusions about
 216 causative relationships.

217 Future prospective studies with larger, more diverse
 218 populations are recommended to validate these findings
 219 and explore the underlying genetic, environmental, and
 220 lifestyle factors contributing to the high prevalence of thyroid
 221 lesions in Pakistan. Moreover, establishing a centralized
 222 thyroid registry in Pakistan would enhance the accuracy of
 223 epidemiological data and facilitate more comprehensive
 224 research on thyroid pathology.

Conclusion

225 The findings of the study reveal a predominance of thyroid
 226 lesions in males, especially in younger adults while neoplastic
 227 lesions being more common than the non-neoplastic
 228 conditions in the local population. Papillary carcinoma
 229 emerged as the sole malignant thyroid lesion, highlighting its
 230 significance within the study population.
 231

Acknowledgement

232 The authors would like to acknowledge Dr. Aneeqa Aslam, Senior
 233 Dentist at CMH Lahore Medical College Lahore for data collection
 234 and interpretation. The authors would also like to thank the Prof.
 235 Aman-ur-Rehman, the Head of Histopathology Department of
 236 Sheikh Zayed Hospital Lahore, Pakistan, for allowing the data
 237 collection and for his support during data acquisition.
 238

List of abbreviations

CMH Combined Military Hospital 240

Conflicts of interest

None to declare. 242

Grant support and financial disclosure

None to disclose. 244

Ethics approval

245 The study was approved by the Institutional Review Board of
 246 Combined Military Hospital Medical and Dental College, Lahore,
 247 vide Letter No: Case#.631/ERC/CMH/LMC dated 25-9-2021.
 248

Authors contributions

249 **RYS:** Conception and design, Critical revision of the manuscript for
 250 important intellectual content, Methodology, Investigation, Draft
 251 preparation.
 252

253 **NM:** Conception and design, Analysis and interpretation of the
 254 data, Drafting of the article, Statistical analysis, Data collection,
 255 Draft preparation.

256 **AS:** Conception and design, Critical revision of the article for
 257 important intellectual content, Drafting of the manuscript, Data
 258 collection.

259 **MQ:** Collection and assembly of data, Drafting of the manuscript,
 260 Data analysis, Interpretation of results.

261 **FY:** Literature search, Critical revision of the manuscript for
 262 important intellectual content, Data interpretation, Proofreading.

263 **HZR:** Literature search, Critical revision of the manuscript for
 264 important intellectual content, Drafting of the manuscript.

265 **ALL AUTHORS:** Approval and responsibility of the final version of
 266 the manuscript to be published.

Author details

267 Raja Yasser Shahbaz¹, Natalia Malik², Amna Sohail², Mustafa
 268 Qadeer³, Faiqua Yasser⁴, Hina Zafar Raja⁵

270 1. Department of Medicine, Rashid Latif Khan University Medical
 271 College, Lahore, Pakistan

272 2. Resident Prosthodontic Department, Institute of Dentistry, CMH
 273 Lahore Medical College, Lahore, Pakistan

274 3. Department of Oral Biology, Institute of Dentistry, CMH Lahore
 275 Medical College, Lahore, Pakistan

- 276 4. Head of Department of Oral Pathology, Institute of Dentistry,
277 CMH Lahore Medical College, Lahore, Pakistan
- 278 5. Head of Prosthodontic Department, Rahbar College of Dentistry,
279 CMH Lahore Medical College, Lahore, Pakistan
- 280 **References**
- 281 1. Ghartimagar D, Ghosh A, Shrestha MK, Thapa S, Talwar OP.
282 Histopathological spectrum of non-neoplastic and neoplastic
283 lesions of thyroid: a descriptive cross-sectional study. *JNMA*.
284 2020;58(231):856. <https://doi.org/10.31729/jnma.5038>
- 285 2. Rajagopal JA, Patil SB, Mane MA. Histopathological assessment
286 of non-neoplastic thyroid lesions-a cross-sectional study. *IP*
287 *Arch Cytol Histopathology Res*. 2021;6(1):35–40. <https://doi.org/10.18231/j.achr.2021.009>
- 288 3. Chen DW, Lang BH, McLeod DS, Newbold K, Haymart MR.
289 Thyroid cancer. *Lancet*. 2023;401(10387):1531–44. [https://doi.org/10.1016/S0140-6736\(23\)00020-X](https://doi.org/10.1016/S0140-6736(23)00020-X)
- 290 4. Aljabri KS, Bokhari SA, Al Shareef MA, Khan PM. An 18-year
291 study of thyroid carcinoma in the western region of Saudi
292 Arabia: a retrospective single-center study in a community
293 hospital. *Ann Saudi Med*. 2018;38(5):336–43. <https://doi.org/10.5144/0256-4947.2018.336>
- 294 5. Alawadhi R, Matakah A, Alzaabi S, Ahmed N, Alduaij A, Sabri
295 A, et al. Epidemiology and surgical characteristics of thyroid
296 cancer in United Arab Emirates: review of 100 consecutive
297 patients. *J Diabetes Endocrine Pract*. 2020;3(02):79–83.
298 https://doi.org/10.4103/jdep.jdep_11_19
- 299 6. Khan F, Hilal K, Ali I, Samad M, Tariq R, Ahmad W, et al.
300 Hospital-based ultra-sonographic prevalence and spectrum
301 of thyroid incidentalomas in Pakistani population. *Cureus*.
302 2021 Aug 11;13(8):e17087. doi: 10.7759/cureus.17087
- 303 7. Iqahtani SM. Cytological patterns of thyroid lesions in Najran,
304 Saudi Arabia: a 5-year retrospective study. *Saudi Med J*. 2022
305 Jul;43(7):735–42. doi: 10.15537/smj.2022.43.7.20220223
- 306 8. Almansoori A, Busch H, Bendardaf R, Hamoudi R.
307 Thyroid cancer incidence in the United Arab Emirates: a
308 retrospective study on association with age and gender.
309 *F1000Research*. 2022;11:338. <https://doi.org/10.12688/f1000research.76121.2>
- 310 9. Zahid MA, Madiha A, Rabia A. Frequency of thyroid lesions
311 at pathology department of King Edward Medical University
312 Lahore. *PJMHS*. 2022;16(03):146–9. Available from: <https://pjmhsonline.com/index.php/pjmhs/article/view/282>
- 313 10. Furqan S, Ahmed A, Batool S, Islam N. Outcome analysis of
314 differentiated thyroid cancer: experience from tertiary care
315 in Karachi. *Pak J Med Sci*. 2024;40(11):2631. <https://doi.org/10.12669/pjms.40.11.7036>
- 316 11. Iftikhar A, Naseeb AK, Khwaja A, Mati H, Karim K, Hameeda
317 N. Patterns of differentiated thyroid cancer in Baluchistan
318 Province of Pakistan: some initial observations. *Med J*
319 *Malays*. 2011;66(4):322–5. <https://europepmc.org/article/med/22299551>
- 320 12. Dalwani AG, Baloch TA, Munir A, Shaikh AA, Khaskheli GA,
321 Laghari AA. Clinical presentation of carcinoma of thyroid
322 and its treatment options. *J Pharm Res Int*. 2021;33(11):1–6.
323 <https://doi.org/10.9734/jpr/2021/v33i1131238>
- 324 13. Jung CK, Bychkov A, Kakudo K. Update from the 2022 World
325 Health Organization classification of thyroid tumors: a
326 standardized diagnostic approach. *Endocrinol Metab (Seoul)*.
327 2022 Oct;37(5):703–18. doi: 10.3803/EnM.2022.1553
- 328 14. Sajisevi M, Caulley L, Eskander A, Du YJ, Auh E, Karabachev
329 A, et al. Evaluating the rising incidence of thyroid cancer
330 and thyroid nodule detection modes: a multinational,
331 multi-institutional analysis. *JAMA Otolaryngol–Head*
332 *Neck Surg*. 2022;148(9):811–8. <https://doi.org/10.1001/jamaoto.2022.1743>
- 333 15. Rossi ED, Pantanowitz L, Hornick JL. A worldwide journey
334 of thyroid cancer incidence centred on tumour histology.
335 *Lancet Diabetes Endocrinol*. 2021;9(4):193–4. [https://doi.org/10.1016/S2213-8587\(21\)00049-8](https://doi.org/10.1016/S2213-8587(21)00049-8)
- 336 16. Naseem M, Ali S, Qadir S, Riaz A, Monawwer A, Tahir B, et
337 al. Trends of pathological findings in patients with thyroid
338 diseases: a single-center, retrospective study. *Clin Med*
339 *Insights Endocrinol Diabetes*. 2024;17:11795514241299709.
340 <https://doi.org/10.1177/11795514241299709>
- 341 17. Ahsan J, Khan N, Parveen B, Butt AM, Sana F. Frequency of
342 thyroid lesions in a tertiary care Hospital in Peshawar. *Ann*
343 *PIMS-Shaheed Zulfiqar Ali Bhutto Med Univ*. 2022;18(4):309–
344 12. <https://doi.org/10.48036/apims.v18i4.682>
- 345 18. Khan L, Khan I, Jomezai AK, Magsi SS, Khan N, Riaz J. Frequency
346 of thyroid carcinoma in multi nodular goiter. *Pak J Med*
347 *Health Sci*. 2023;17(02):237–40. <https://doi.org/https://doi.org/10.53350/pjmhs2023172237>
- 348 19. Saran S. Multinodular goiter. In: Agrawal NK, editor. *Goiter-*
349 *Causes and Treatment*. London, UK: IntechOpen; 2020. pp
350 99–110.
- 351 20. SamieeRad F, Emami A. Synchronous occurrence of
352 papillary thyroid carcinoma and medullary carcinoma in the
353 setting of Hashimoto’s thyroiditis and multi nodular goiter.
354 *Iran J Pathol*. 2022;17(1):91. <https://doi.org/10.30699/IJP.2021.527288.2606>
- 355 21. Li M, Dal Maso L, Vaccarella S. Global trends in thyroid cancer
356 incidence and the impact of overdiagnosis. *Lancet Diabetes*
357 *Endocrinol*. 2020;8(6):468–70. [https://doi.org/10.1016/S2213-8587\(20\)30115-7](https://doi.org/10.1016/S2213-8587(20)30115-7)
- 358 22. Flemban AF, Kabrah S, Alahmadi H, Alqurashi RK, Turaes
359 AS, Almaghrabi R, et al. Patterns of thyroid cancer
360 mortality and incidence in Saudi Arabia: a 30-year study.
361 *Diagnostics*. 2022;12(11):2716. <https://doi.org/10.3390/diagnostics12112716>
- 362 23. Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi
363 S, Vaccarella S, et al. Thyroid cancer incidence trends
364 by histology in 25 countries: a population-based study.
365 *Lancet Diabetes Endocrinol*. 2021;9(4):225–34. [https://doi.org/10.1016/S2213-8587\(21\)00027-9](https://doi.org/10.1016/S2213-8587(21)00027-9)
- 366 24. Li M, Dal Maso L, Pizzato M, Vaccarella S. Evolving
367 epidemiological patterns of thyroid cancer and estimates
368 of overdiagnosis in 2013–17 in 63 countries worldwide:
369 a population-based study. *Lancet Diabetes Endocrinol*.
370 2024;12(11):824–36. [https://doi.org/10.1016/S2213-8587\(24\)00223-7](https://doi.org/10.1016/S2213-8587(24)00223-7)
- 371 25. Mikulska AA, Karaźniewicz-Łada M, Filipowicz D, Ruchała
372 M, Głowska FK. Metabolic characteristics of hashimoto’s
373 thyroiditis patients and the role of microelements and diet
374 in the disease management - an overview. *Int J Mol Sci*.
375 2022;23(12):6580. <https://doi.org/10.3390/ijms23126580>
- 376 26. Trinh CT. A review of the pathology, diagnosis and management
377 of colloid goitre. *Eur Endocrinol*. 2020;16(2):131. <https://doi.org/10.17925/EE.2020.16.2.131>